Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Central Diabetes Insipidus

In brief

The investigator hypothesize that low-dose MDMA (3,4-methylenedioxymethamphetamine) will produce a sufficiently strong oxytocin stimulation in healthy controls and no relevant increase in patients. This study will confirm previously published data and provide important safety data with low-dose MDMA stimulation testing.

Key facts

Study ID
NCT06789705
Run by
University Hospital, Basel, Switzerland
People needed
24
Starts
2025-01-27
Expected to finish
2026-12-01
Last updated by the study team
2025-02-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.